Studies on a New Drug Show Comedy of Errors When Not Enough Patients are Tested

A lesson in the safety and efficacy of new drugs is very simple: small studies are bad, big studies are good. This lesson has been proven all over again with a big trial of a heart failure drug called Natrecor (generic name: nesiritide).

Small studies made the drug look worrisome for some bad side effects. Now a big study has found those worries misplaced -- but it also found the drug doesn't work all that well for its main purpose of preventing fluid accumulation in the lungs of heart failure patients -- symptoms that give them a terrible feeling of near drowning.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Health Updates, Personal Injury Updates, Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patrick Malone & Associates P.C. | DC Injury Lawyers | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

CONNECT

About Patrick Malone: Patrick Malone is a leading patient safety advocate and attorney who... View Profile »


Follow Patrick Malone & Associates P.C. | DC Injury Lawyers:

Reporters on Deadline